Novartis slashes Cosentyx price by 55% with direct-to-patient sales in 2025

Novartis will begin selling its psoriasis drug Cosentyx directly to US patients from November 1, 2025. The move comes as part of a new direct-to-patient (DTP) platform aimed at cutting costs and simplifying access. Victor Bultó, President of Novartis in the US, described the launch as a first step in removing barriers between patients and their treatments.

Cosentyx is Novartis' top-selling product in the US and is approved for several immune-mediated inflammatory diseases. Under the new system, patients paying in cash will buy the drug at a price matching the average savings secured by insurers and pharmacy benefit managers.

The DTP platform will offer Cosentyx at a 55% discount compared to its standard list price. This approach bypasses traditional distribution channels, allowing Novartis to pass savings directly to patients. For now, the company has no plans to extend this model to any other medicines in the US. Bultó highlighted that the initiative seeks to explore more efficient ways of reaching patients. The platform's launch reflects a broader effort to streamline access to essential treatments.

Starting in November 2025, eligible patients will purchase Cosentyx at a significantly reduced rate. The discount aligns with savings typically negotiated by insurers, making the drug more affordable for those paying out of pocket. Novartis has confirmed that no other products will follow this direct-sale approach in the US at present.